Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGFbi NK cells
- Development stage
- Unknown
- Lead developer
- University of Kentucky
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TGFbi NK cells (TiNK) are an investigational allogeneic (universal donor) natural killer (NK) cell therapy. These cells are expanded ex vivo and "imprinted" with transforming growth factor-beta (TGF-beta), a process intended to enhance their anti-tumor activity, metabolic fitness, and persistence within the immunosuppressive tumor microenvironment. In clinical trials led by Elvira Umyarova at the University of Kentucky, these cells are being evaluated for the treatment of relapsed or refractory multiple myeloma, particularly in patients who have progressed after BCMA-targeted therapies. The therapy is typically administered intravenously following lymphodepleting chemotherapy and in combination with isatuximab, a CD38-targeting monoclonal antibody, to facilitate antibody-dependent cellular cytotoxicity (ADCC).
- Other names
- Universal Donor Expanded TGF-beta-imprinted NK CellsTGF-beta-imprinted NK cellsTGF-beta-imprinted Natural Killer Cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MAFA (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)
Beyond the preview
Go deeper on TGFbi NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGFbi NK cells.